• Spero Therapeutics posted a net loss of $7.2 million for the quarter ended March 31, 2026, narrowing from $13.87 million a year earlier.
• Revenue fell to $258,000 from $5.87 million, reflecting $258,000 of collaboration revenue and no grant revenue.
• Operating loss narrowed to $7.54 million from $14.73 million as operating expenses dropped to $7.8 million from $20.61 million.
• Cash and cash equivalents totaled $56.1 million at March 31, 2026; February receipt of a $25 million GSK milestone followed the December 2025 NDA resubmission for tebipenem HBr, with a June 18, 2026 PDUFA date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-221591), on May 13, 2026, and is solely responsible for the information contained therein.